Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00405080 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00405080 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 12 participants.
The verdict
NCT00405080, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will examine what the body does while taking GW679769 alone and together with rifampin in healthy adult subjects.
Interventions
- DRUG GW679769 (Casopitant) oral tablets
- DRUG Rifampin oral capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2006-11-11 |
| Est. Completion | 2007-01-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00405080
The ClinicalTrials.gov registry entry for NCT00405080 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GW679769 (Casopitant) oral tablets is the first listed.
NCT00405080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00405080 about?
NCT00405080 is a clinical study titled "A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).". This study will examine what the body does while taking GW679769 alone and together with rifampin in healthy adult subjects.
What is the current status of trial NCT00405080?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2006-11-11. Estimated completion is 2007-01-05.
What interventions are being tested in trial NCT00405080?
The interventions under investigation include: GW679769 (Casopitant) oral tablets (DRUG), Rifampin oral capsules (DRUG).
Who is sponsoring clinical trial NCT00405080?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.